Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
Schiller
Ampronix

Counterfeit Contraceptives Rife in South America

By HospiMedica International staff writers
Posted on 30 Apr 2014
A survey of emergency contraceptive pills (ECPs) in Peru has found that 28% of the batches studied were either of substandard quality or falsified.

Researchers at the Georgia Institute of Technology (GATech; Atlanta, USA), The University of Oxford (United Kingdom), and other institutions developed an analytical strategy to assess ECP medicine quality in Peru. For the study, samples of ECPs were purchased at 15 pharmacies and distributors in Lima (Peru). The tablets were collected from 25 different production batches (60 tablets each), encompassing 20 brands labeled as manufactured in nine countries (Argentina, Chile, China, Colombia, Hungary, India, Pakistan, Peru, and Uruguay).

The researchers used a tiered multiplatform approach to examine the tablets. First, ambient mass spectrometry was used to obtain a real-time signature of the tablet's chemical composition. They then examined the presence, identity, and amount of the active ingredient, and tested if the tablet dissolves properly. Since sophisticated fakes might pass all these tests, the researchers also examined excipients, such as lactose and cellulose. In all, 7 different batches showed inadequate release or improper amounts of the active ingredient, levonorgestrel, and one batch was found to contain a wrong active ingredient. The study was published on April 18, 2014, in PLoS One.

“A woman who does not want to get pregnant and takes these emergency contraceptives will get pregnant,” said study author Prof. Facundo Fernández, PhD, of the GATech school of chemistry and biochemistry. “We detected that the active ingredient was not there in one batch, instead those samples had a drug called sulfamethoxazole. It's a very common antibiotic. It can cause serious adverse reactions in some patients.”

Falsified drugs are a major problem in developing countries, and have been reported in Nigeria, Ghana, Kenya, Angola, South America, and even the United States. Just as concerning are other poor quality medications, such as degraded or substandard drugs. Degraded drugs are those that lost their efficacy over time, for example after prolonged exposure to the sun in an open air market. Substandard drugs are made by an approved factory, but do not contain the right active ingredient, contain less active ingredient than they should, or might not dissolve properly.

Related Links:

Georgia Institute of Technology
The University of Oxford



Centurion Service
MinXray
Bovie Medical

Channels

Critical Care

view channel
Image: The Trellis peripheral infusion system (Photo courtesy of Covidien).

Thrombolytic Drug Delivery Device Dissolves Blood Clots

A redesigned peripheral infusion system enables focused treatment of blood clots to avoid potential post-thrombotic syndrome (PTS). The updated Trellis peripheral infusion system is a pharmacomechanical... Read more

Surgical Techniques

view channel

Gold Nanoparticles Prevent Infection on Orthopedic Implants

Gold (Au) nanoparticles help prevent the formation of antibiotic resistant biofilm on the surface of orthopedic implants, according to a new study. Researchers at the Shanghai Institute of Ceramics (CIS; China) extrapolated that since gold nanoparticles can pass electrons to titanium dioxide (TiO2), they could be used... Read more

Health IT

view channel
Image: The Health eResearch Center UV2 supercomputer (Photo courtesy of HeRC).

Supercomputer Accelerates Pace of Health Research

The University of Manchester (United Kingdom) is financing a new supercomputer system that can analyze bigger and more complex sets of information. The Health eResearch Center (HeRC; Manchester, United... Read more

Business

view channel

Spectranetics Completes Acquisition of AngioScore

Spectranetics (Colorado Springs, CO, USA) has completed the acquisition of AngioScore (Fremont, CA, USA), a leading developer, manufacturer, and marketer of cardiovascular specialty balloons. The transaction, for USD 230 million in cash and contingent commercial and regulatory milestone payments, will combine differentiated,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.